Jupiter Endovascular Announces Positive Results From SPIRARE II Pivotal Trial at EuroPCR 2026

Vertex Pulmonary Embolectomy System demonstrated significant right heart recovery, low adverse event rates, and reproducible performance across high-severity PE patients

Excerpt from the Press Release:

MENLO PARK, Calif.–(BUSINESS WIRE)–Jupiter Endovascular, Inc. today announced that the SPIRARE II pivotal trial evaluating the use of the company’s Vertex™ Pulmonary Embolectomy System in patients with acute, intermediate-risk pulmonary embolism (PE) met both of its primary endpoints, demonstrating meaningful heart recovery and clinical safety. Late-breaking data from the trial were presented today by Catalin Toma, MD, Director of Interventional Cardiology at the UPMC Heart and Vascular Institute and the trial’s Global Co-Principal Investigator, at EuroPCR 2026 in Paris, France.

“Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” said Sameh Sayfo, MD, Pulmonary Embolism Response Team Director at Baylor Scott & White The Heart Hospital – Plano and Global Co-Principal Investigator of SPIRARE II. “Historically, the ability to achieve both safe right-heart navigation and the procedural stability necessary for controlled PE thrombectomy has represented a significant limitation in consistently normalizing hemodynamics. What makes SPIRARE II particularly compelling is the opportunity to evaluate a system that may enhance not only clot extraction, but also the overall quality, precision, and physiologic impact of the intervention.”

The Vertex system leverages the company’s patented Transforming Fixation (TFX) platform technology in a novel catheter system designed to navigate flexibly through the right heart and then stabilize on-demand in the pulmonary arteries for precise intervention.

Click the button below to read the entire Press Release:

Continue Reading The Press Release